Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESSO 45 | Assessing mesenteric involvement before cytoreductive surgery for peritoneal malignancies

Francesca Nava • 4 Nov 2026
ESSO 45
Gastrointestinal Cancer

Francesca Nava, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the clinical assessment and diagnostic approach for patients with peritoneal surface malignancies requiring cytoreductive surgery, emphasizing the importance of CT imaging to evaluate mesenteric involvement followed by laparoscopy to assess infiltration patterns. Histological findings drive treatment decisions based on tumor biology. Dr Nava advocates for integrating laparoscopic assessment into standard cytoreductive surgery techniques to optimize complete cytoreduction outcomes for patients. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Peritonectomy as a surgical technique was firstly presented to the academic world in 2009, when Dr...
Peritonectomy as a surgical technique was firstly presented to the academic world in 2009, when Dr. De Bracco described it. But since then, it’s only been added only recently, two years ago, during the PSOGIC consensus in Lyon, to the recent techniques of peritonectomies. And in literature, there are no reports on outcomes whatsoever. So we decided to look at our own cohort, the National Cancer Institute of Mesenterica, own cohort, the And basically, analyze what the outcomes are when this technique is actually added to complex surgeries as CRS HIPEC. Basically, what came out of the analysis, which was quite a complex analysis, because it’s difficult to confront these patients with patients which did not receive the same treatment, is that there is no added morbidity to the technique, even though it is fair to announce that this is a quite complex one. So, there is a surgical burden that is added to a still complex surgery.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals